AURA 3, trial summary

A randomised clinical trial investigating the effect of Osimertinib versus in patients with EGFR T790M mutation-positive, locally-advanced or metastatic NSCLC, whose disease had progressed after 1st-line EGFR tyrosine kinase inhibitor (TKI) therapy.

NCT02151981    N Engl J Med 2017 Feb 16;376:629-640  




Studied treatment
Control treatment



Patients patients with EGFR T790M mutation-positive, locally-advanced or metastatic NSCLC, whose disease had progressed after 1st-line EGFR tyrosine kinase inhibitor (TKI) therapy.
Group sizes -9 / -9
patients



Blindness Inclusion period
Follow-up duration Centers
Lost to FU geographical localisation
Primary endpoint Design



EndpointX1N1X0N0TE95% CI OS - -9 - -9 no data PFS - -9 - -9 no data ORR - -9 - -9 no data0,22,01,0


Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med 2017 Feb 16;376:629-640     [PMID: 27959700]   link to pdf  



Registering number NCT02151981 (see trial on clinicaltrials.gov)
Code Name

 




Appears in following systematic reviews: